Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Athenex stock price, quote, forecast and news

ATNX
US04685N1037
A2DTE9

Price

0.02
Today +/-
+0
Today %
+0 %
P

Athenex stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Athenex stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Athenex stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Athenex stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Athenex's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Athenex Stock Price History

DateAthenex Price
10/2/20230.02 undefined
9/29/20230.02 undefined

Athenex Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Athenex, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Athenex from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Athenex’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Athenex. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Athenex’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Athenex’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Athenex’s growth potential.

Athenex Revenue, EBIT and net profit per share

DateAthenex RevenueAthenex EBITAthenex Net Income
2026e155.39 M undefined-7.18 M undefined-79.46 M undefined
2025e152.58 M undefined-4.53 M undefined-57.03 M undefined
2024e89 M undefined-46.4 M undefined-357.24 M undefined
2023e86.63 M undefined-54.03 M undefined-741.14 M undefined
2022102.82 M undefined-69.94 M undefined-103.43 M undefined
202195.37 M undefined-109.42 M undefined-199.77 M undefined
2020144.39 M undefined-119.73 M undefined-146.18 M undefined
2019101.2 M undefined-119.5 M undefined-123.7 M undefined
201889.1 M undefined-126.8 M undefined-117.4 M undefined
201738 M undefined-110 M undefined-131.2 M undefined
201620.6 M undefined-85.7 M undefined-87.7 M undefined
201513.9 M undefined-50.7 M undefined-50.6 M undefined
20141.2 M undefined-17.7 M undefined-17.7 M undefined

Athenex Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2014201520162017201820192020202120222023e2024e2025e2026e
113203889101144951028688152155
-1,200.0053.8590.00134.2113.4842.57-34.037.37-15.692.3372.731.97
---31.5847.1930.6934.0333.6825.49----
0001242314932260000
-17-50-85-110-126-119-119-109-69-54-46-4-7
-1,700.00-384.62-425.00-289.47-141.57-117.82-82.64-114.74-67.65-62.79-52.27-2.63-4.52
-17-50-87-131-117-123-146-199-103-741-357-57-79
-194.1274.0050.57-10.695.1318.7036.30-48.24619.42-51.82-84.0338.60
55.255.255.25064.674.14.255.26.540000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The Athenex Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Athenex is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201420152016201720182019202020212022
                 
2855.841.851107.4160.8208.2245.4131.51
0.33.82.88.51316.723.626.6427.87
000000000
03.34.216.628.832.628.8534.6942.65
0.72.33.27.721.720.831.2926.6722.9
2965.25283.8170.9230.9291.96133.4124.93
0.86.35.89.711.43242.3134.226.04
0.82.40.30.300000
000000000
0.57.28.58.610.88.510.2271.972.11
4.63837.637.837.538.538.8900
01.41.80.30.500.9527.940.97
6.755.35456.760.27992.37134.0579.13
35.7120.5106140.5231.1309.9384.33267.45204.06
                 
000100100100951119
0.090.210.240.420.590.760.90.971.02
-56.8-107.4-195.1-326.3-443.7-567.5-713.64-913.41-1,016.84
100-200-1,300-100-700-600-1,134-487887
000000000
29.499.141.297.5146.8195.6187.1858.621.25
26.37.216.71323.318.6716.7433.68
3.6418.725.437.546.938.3622.2732.88
0.26.10.21.60.20.43.110.1611.19
000000000
01.31.91.510.92.0146.8837.13
5.817.72845.251.771.562.1496.05114.88
02.431.10.545.852.4146.58103.4686.84
00.70.20000.061.751.75
21.711.94.14.810.210.2131.7424.77
24.843.24.650.662.6156.84136.95113.36
7.822.571.249.8102.3134.1218.98233228.24
37.2121.6112.4147.3249.1329.7406.16291.61229.49
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Athenex provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Athenex's financial health and stability.

Assets

Athenex's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Athenex must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Athenex after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Athenex's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201420152016201720182019202020212022
-17-50-87-131-128-125-144-160-98
002333432
0000000-100
1015-3-2712-20-1811
3162250431129449
00002462011
000000300
-11-33-47-81-109-97-131-142-75
0-3-4-6-3-17-8-2-2
-14-162-10-487-11810457
-14-136-3-4525-11010759
000000000
003628495900-23
3177278127163135239
3176359616916720921
---4.00-10.00-7.00-1.00-17.00--14.00
000000000
425-1061077-41-34-16
-12.01-37.12-52.06-88.5-112.82-115.21-140.08-144.99-77.07
000000000

Athenex stock margins

The Athenex margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Athenex. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Athenex.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Athenex's sales revenue. A higher gross margin percentage indicates that the Athenex retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Athenex's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Athenex's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Athenex's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Athenex. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Athenex's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Athenex Margin History

Athenex Gross marginAthenex Profit marginAthenex EBIT marginAthenex Profit margin
2026e25.97 %-4.62 %-51.14 %
2025e25.97 %-2.97 %-37.38 %
2024e25.97 %-52.13 %-401.41 %
2023e25.97 %-62.37 %-855.52 %
202225.97 %-68.02 %-100.59 %
202134.05 %-114.73 %-209.47 %
202033.96 %-82.92 %-101.24 %
201931.23 %-118.08 %-122.23 %
201847.25 %-142.31 %-131.76 %
201733.95 %-289.47 %-345.26 %
20163.88 %-416.02 %-425.73 %
20155.76 %-364.75 %-364.03 %
201458.33 %-1,475 %-1,475 %

Athenex Stock Sales Revenue, EBIT, Earnings per Share

The Athenex earnings per share therefore indicates how much revenue Athenex has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Athenex earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Athenex's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Athenex’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Athenex's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Athenex Revenue, EBIT and net profit per share

DateAthenex Sales per ShareAthenex EBIT per shareAthenex Earnings per Share
2026e0.99 undefined0 undefined-0.5 undefined
2025e0.97 undefined0 undefined-0.36 undefined
2024e0.57 undefined0 undefined-2.27 undefined
2023e0.55 undefined0 undefined-4.71 undefined
202215.72 undefined-10.69 undefined-15.81 undefined
202118.35 undefined-21.05 undefined-38.44 undefined
202033.94 undefined-28.14 undefined-34.36 undefined
20191.37 undefined-1.61 undefined-1.67 undefined
20181.38 undefined-1.96 undefined-1.82 undefined
20170.76 undefined-2.2 undefined-2.62 undefined
20160.37 undefined-1.55 undefined-1.59 undefined
20150.25 undefined-0.92 undefined-0.92 undefined
20140.02 undefined-0.32 undefined-0.32 undefined

Athenex business model

Athenex Inc was founded in 2003 and is headquartered in Buffalo, New York. The company specializes in the development and marketing of innovative drugs and therapies for the treatment of cancer and other serious diseases. Athenex's business model is based on collaboration with other companies and research institutions. The company works closely with academic partners to identify and develop new technologies and active ingredients. Athenex has also entered into several collaboration agreements with major pharmaceutical companies to facilitate the marketing of its products. The company has multiple divisions: Athenex Pharmaceutical Division, Athenex Oncology Division, and Athenex Pharmaceutical Technology Division. The Athenex Pharmaceutical Division focuses on the development and marketing of drugs for the treatment of cancer and other serious illnesses. The company has several promising drug candidates in its pipeline, including Oratopo, a drug for the treatment of breast cancer, and KX-2-391, a drug for the treatment of prostate cancer. The Athenex Oncology Division focuses on the development and marketing of innovative cancer treatment methods. The company has several promising therapy approaches in its pipeline, including an immunological cancer treatment based on activating the immune system to fight cancer cells. The Athenex Pharmaceutical Technology Division utilizes advanced technologies to improve the effectiveness and tolerability of drugs, including novel drug delivery systems and innovative packaging forms. Athenex also offers a wide range of products and services for the pharmaceutical industry, including drug development and manufacturing, as well as the supply of active ingredients and excipients. Overall, Athenex has a broad and interesting business model and a promising portfolio of drug candidates and therapy approaches in its pipeline. The company has also established strong partnerships with other companies and research institutions to advance its development and marketing of drugs and therapies. Athenex is one of the most popular companies on Eulerpool.com.

Athenex SWOT Analysis

Strengths

Athenex Inc is a highly innovative biopharmaceutical company that focuses on the development and commercialization of novel cancer treatments.

The company has a strong portfolio of proprietary drugs and drug delivery technologies, giving it a competitive edge in the market.

Athenex's strategic partnerships with academic institutions and other pharmaceutical companies provide access to cutting-edge research and potential collaboration opportunities.

Weaknesses

Athenex faces the risk of high research and development costs associated with the development of new drugs, which could impact its profitability.

The company heavily relies on the success of its drug candidates, and any setbacks or failures in clinical trials could have a detrimental effect on its reputation and financial performance.

Being a relatively small biopharmaceutical company, Athenex has limited resources compared to larger competitors, which could hinder its ability to effectively compete in the market.

Opportunities

The increasing prevalence of cancer worldwide presents a significant market opportunity for Athenex, as there is a growing demand for effective cancer treatments.

Athenex can capitalize on the trend towards personalized medicine by leveraging its expertise in developing targeted therapies that cater to specific patient populations.

Expansion into international markets can provide Athenex with access to a larger customer base and diversify its revenue streams.

Threats

The biopharmaceutical industry is highly competitive, with numerous well-established players. Athenex faces the risk of intense competition, pricing pressures, and potential market saturation.

Regulatory approvals and compliance requirements pose a significant challenge for Athenex, as any delays or failures in obtaining necessary approvals can hinder the commercialization and success of its drugs.

Emerging technologies and advancements in cancer research could render Athenex's existing technologies and therapies obsolete, making it crucial for the company to stay at the forefront of innovation.

Athenex Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Athenex Revenue by Segment

Segmente2021202020192018
Product Sales, Net-105.27 M USD--
Product92.26 M USD---
License and other revenue27.92 M USD39.12 M USD--
Product Sales, Net--80.54 M USD56.39 M USD
License Revenue-38.83 M USD--
License fees and consulting revenue---32.39 M USD
License26.83 M USD---
Licence and other revenue--20.69 M USD-
Grant Revenue---319,000 USD
Active Pharmaceutical Ingredient sales----
Commercial product sales----
Contract manufacturing revenue----
Grant revenue----
Medical device sales----
Commercial product sales86.77 M USD101.59 M USD--
Active Pharmaceutical Ingredient sales3.99 M USD3.6 M USD--
Contract manufacturing revenue1.51 M USD85,000 USD--
Product and Service, Other1.09 M USD---
Other Revenue-290,000 USD--
Licensed IP-1 M USD--
Oncology Innovation Platform26.87 M USD38.85 M USD--
Commercial Platform66.99 M USD89.57 M USD--
Global Supply Chain Platform26.32 M USD15.97 M USD--
Commercial Platform--50.43 M USD30.43 M USD
Global Supply Chain Platform--30.24 M USD25.9 M USD
Oncology Innovation Platform--20.56 M USD32.78 M USD

Athenex Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Athenex Revenue by Segment

DateAustriaAUSTRIAChinaCHINAIndiaINDIAKorea (South), WonKOREA, REPUBLIC OFOther CountriesOther Foreign CountriesOther foreign countries including AustriaSouth KoreaSpainSPAINTaiwanUnited KingdomUnited States
2021-115,000 USD-2.67 M USD-906,000 USD1.11 M USD1.11 M USD878,000 USD-1.04 M USD--47,000 USD--114.46 M USD
2020226,000 USD-39.8 M USD------364,000 USD590,000 USD2.35 M USD---19.29 M USD82.36 M USD
20194.42 M USD-2.11 M USD-3.07 M USD----2.82 M USD--20 M USD--1.02 M USD67.79 M USD
20189.57 M USD-4.42 M USD-3.46 M USD----3.75 M USD--30 M USD---37.9 M USD
20173.96 M USD-2.8 M USD-8.48 M USD----2.37 M USD----500,000 USD-19.93 M USD

Athenex Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Athenex historical P/E ratio, EBIT, and P/S ratio.

Athenex shares outstanding

The number of shares was Athenex in 2023 — This indicates how many shares 6.541 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Athenex earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Athenex's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Athenex’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Athenex's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Athenex Stock splits

In Athenex's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Athenex.

Athenex list of shareholders

%
Name
Stocks
Change
Date
0.49338 % Perceptive Advisors LLC776,62302/1/2023
0.32573 % IP Group PLC512,73809/23/2022
0.20698 % Millennium Management LLC325,807117,31612/31/2022
0.19712 % Ma (Huateng)310,29009/23/2022
0.17036 % The Vanguard Group, Inc.268,1586312/31/2022
0.13633 % Lau Johnson Yiu Nam214,5972,5602/24/2023
0.09163 % Fok (Manson)144,2312,0161/13/2023
0.06353 % Alyeska Investment Group, L.P.100,000012/31/2022
0.05000 % UBS Financial Services, Inc.78,7053,86712/31/2022
0.04612 % Empery Asset Management, L.P.72,60572,6059/30/2022
1
2
3
4
5
...
10

Most common questions regarding Athenex

What values and corporate philosophy does Athenex represent?

Athenex Inc represents a commitment to innovation, integrity, and patient-centered care. The company aims to develop and deliver innovative therapies to improve the lives of patients around the world. With a strong focus on research and development, Athenex Inc prioritizes groundbreaking solutions in the fields of oncology and immunology. Their corporate philosophy emphasizes collaboration, excellence, and a passion for scientific advancements. By harnessing cutting-edge technologies and fostering strategic partnerships, Athenex Inc strives to address unmet medical needs and make a positive impact in the healthcare industry.

In which countries and regions is Athenex primarily present?

Athenex Inc is primarily present in the United States and various regions within Asia. The company has a strong presence in China, often referred to as its core market, where it operates multiple facilities and has established partnerships. Additionally, Athenex Inc has a significant presence in other Asian countries and regions such as Japan, Korea, and Southeast Asia. With its focus on developing and commercializing innovative oncology and immune-oncology products, Athenex Inc continues to expand its global footprint while maintaining a solid presence in the United States and key Asian markets.

What significant milestones has the company Athenex achieved?

Athenex Inc. has achieved several significant milestones in its operations. The company received FDA approval for its oral paclitaxel and encequidar in metastatic breast cancer, providing a new treatment option for patients. Athenex Inc. also secured a strategic partnership with Almirall to commercialize and develop its KX2-391 and KX-01 drugs for the treatment of actinic keratosis and cutaneous squamous cell carcinoma. Furthermore, the company witnessed the successful completion of a Phase III study on oral paclitaxel in gastric cancer, demonstrating positive outcomes. These milestones showcase Athenex Inc.'s dedication to advancing innovative treatments and expanding its therapeutic portfolio.

What is the history and background of the company Athenex?

Athenex Inc is a pharmaceutical company based in the United States. It was founded in 2003 by Dr. Johnson Lau and Dr. Rudolf Kwan. The company specializes in the discovery, development, and commercialization of innovative oncology drugs. Athenex Inc has a diverse pipeline of products, including oral chemotherapy drugs, immunotherapy agents, and targeted therapies. The company has strategic partnerships with various institutions, including the Buffalo Medical Innovation and Commercialization Hub, which aids in the development and manufacturing of its products. With a strong focus on research and development, Athenex Inc continues to strive towards improving treatment options for cancer patients.

Who are the main competitors of Athenex in the market?

The main competitors of Athenex Inc in the market are pharmaceutical companies such as AstraZeneca, Pfizer, and Novartis.

In which industries is Athenex primarily active?

Athenex Inc is primarily active in the biopharmaceutical and oncology industries. The company focuses on the development and commercialization of innovative therapies to treat cancer and other diseases. Athenex is committed to advancing medical science and improving patient outcomes through its research and development efforts. With its expertise in the field, Athenex aims to provide effective and safe treatment options for patients globally.

What is the business model of Athenex?

The business model of Athenex Inc revolves around the development and commercialization of innovative therapies for cancer treatment. The company focuses on both oral and injectable oncology drugs that address unmet medical needs. Athenex employs a vertically integrated approach, combining its research and development capabilities with manufacturing and commercialization expertise. By leveraging its proprietary technology platforms, including Orascovery and Src Kinase Inhibition, Athenex aims to enable more effective and targeted cancer treatments. This strategic model allows the company to bring novel therapies to market more efficiently and broaden its product portfolio, ultimately improving patient outcomes.

What is the P/E ratio of Athenex 2024?

The Athenex P/E ratio is -0.

What is the P/S ratio of Athenex 2024?

The Athenex P/S ratio is 0.

What is the AlleAktien quality score of Athenex?

The AlleAktien quality score for Athenex is 2/10.

What is the revenue of Athenex 2024?

The expected Athenex revenue is 89 M USD.

How high is the profit of Athenex 2024?

The expected Athenex profit is -357.24 M USD.

What is the business model of Athenex

Athenex Inc. is an American biopharmaceutical company specializing in the development and manufacture of innovative drugs for cancer and other diseases. Athenex has various divisions focusing on research and development, pharmaceutical manufacturing, marketing and sales, and biopharmaceutical services. The company uses novel technologies and scientific knowledge in the development of its drugs and has several medications in clinical trials, including oral cancer drugs and specialized antibiotics. Athenex operates state-of-the-art manufacturing facilities in the U.S. and China, producing a wide range of pharmaceuticals. Its marketing and sales team distributes medications for cancer treatments and other diseases both domestically and internationally through strategic partnerships, direct sales, and online platforms. Additionally, Athenex offers biopharmaceutical services such as drug development, clinical trials, analysis, manufacturing, and quality assurance for other companies. The company's product offerings include oncology drugs, immunotherapies, and specialized antibiotics aimed at improving the lives of cancer patients, boosting treatment outcomes, combating antibiotic resistance, and developing new drugs for antibiotic-resistant bacteria strains. Athenex has a strong business model built on years of industry experience and a portfolio of innovative products and services, with a focus on meeting the needs of patients, doctors, and other stakeholders. The company will continue to invest in research and development to enhance its products and services and ensure future growth.

What is the Athenex dividend?

Athenex pays a dividend of 0 USD distributed over payouts per year.

How often does Athenex pay dividends?

The dividend cannot currently be calculated for Athenex or the company does not pay out a dividend.

What is the Athenex ISIN?

The ISIN of Athenex is US04685N1037.

What is the Athenex WKN?

The WKN of Athenex is A2DTE9.

What is the Athenex ticker?

The ticker of Athenex is ATNX.

How much dividend does Athenex pay?

Over the past 12 months, Athenex paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Athenex is expected to pay a dividend of 0 USD.

What is the dividend yield of Athenex?

The current dividend yield of Athenex is .

When does Athenex pay dividends?

Athenex pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Athenex?

Athenex paid dividends every year for the past 0 years.

What is the dividend of Athenex?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Athenex located?

Athenex is assigned to the 'Health' sector.

Wann musste ich die Aktien von Athenex kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Athenex from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Athenex pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Athenex in the year 2023?

In the year 2023, Athenex distributed 0 USD as dividends.

In which currency does Athenex pay out the dividend?

The dividends of Athenex are distributed in USD.

All fundamentals about Athenex

Our stock analysis for Athenex Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Athenex Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.